Certican

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Everolimus (Certican; Novartis Pharma AG, Basel, Switzerland) represents the latest generation of proliferation signal inhibitors… (More)
Is this relevant?
2007
2007
BACKGROUND Everolimus is a proliferation signal-inhibitor recently introduced in heart transplant recipients. To date, little is… (More)
Is this relevant?
2007
2007
BACKGROUND/METHODS This observational study reports on immunosuppression with cyclosporine (CsA) in 38 de novo heart transplant… (More)
Is this relevant?
Review
2005
Review
2005
The calcineurin inhibitors (CNIs) have been the cornerstone of immunosuppressive therapy in recent years, though their… (More)
Is this relevant?
2005
2005
BACKGROUND Everolimus (Certican), a novel proliferation signal inhibitor, allows calcineurin inhibitor dose reduction in… (More)
Is this relevant?
Review
2005
Review
2005
The proliferation signal inhibitor everolimus is efficacious for reducing the incidence of acute rejection and cardiac allograft… (More)
Is this relevant?
Review
2005
Review
2005
The Certican Consensus Conference has produced guidelines to help physicians apply Certican (everolimus) clinical trial data in… (More)
Is this relevant?
2005
2005
Immunosuppressant agents have greatly increased graft and overall survival in heart transplant patients, but some of these agents… (More)
Is this relevant?
2005
2005
BACKGROUND With an increasing number of elderly patients now waiting for a kidney transplant, and the percentage of kidney donors… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection… (More)
Is this relevant?